UNSPSC 51313706: Bosentan hydrate

This classification denotes an endothelin receptor antagonist with the molecular formula C27H29N5O6S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q326023R30, chemically known as benzenesulfonamide, 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'bipyrimidin)-4-yl)-, monohydrate, but more generally known as bosentan hydrate, which bears US NIH Compound Identifier 185462.

European Medicines Agency schedules bosentan hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05877MIG. Most nations, for tariff purposes, schedule bosentan hydrate under HS 29350090. SMILES: CC(C)(C)C1CCC(CC1)S(=O)(=O)NC2C(C(NC(N2)C3NCCCN3)OCCO)OC4CCCCC4OC.O.

UNSPSC 51313706 Bosentan hydrate is a Commodity-code pharmaceutical product with minimal concrete alignment to recent state and local procurement activity. The code nominally refers to a specific pharmaceutical compound used to treat pulmonary arterial hypertension, yet the three most recent opportunities tagged to it—a naloxone and drug deactivation systems procurement, a pharmacy direct-to-manufacturer information-gathering initiative, and a multistate generic pharmaceuticals and OTC products cooperative—do not reflect procurement of bosentan hydrate itself. State and local governments soliciting under this code appear to be purchasing broader pharmaceutical and medication management services rather than this specific active pharmaceutical ingredient or branded formulation. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, spanning Minnesota and Oregon). The fragmented nature of recent activity suggests that bosentan hydrate procurement, if it occurs at all in state and local markets, is subsumed within larger pharmaceutical or formulary management contracts rather than solicited as a standalone commodity.

The geographic spread of recent activity centers on Florida, Texas, and the Upper Midwest (Minnesota and Oregon). The most recent opportunity is Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, with a due date of July 26, 2023 (an apparent date inconsistency in the source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building. The Texas HHS Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements. MMCAP's RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 response deadline, solicits generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with contracts effective July 1, 2026. Because the code shows no recent solicitation of bosentan hydrate specifically, the procurement signal under this code is weak and does not support a clear pursue decision based on demonstrated state and local demand.